Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,600.63
(
-0.36%
)
US TECH 100
23,642.40
(
-0.65%
)
Dow Jones
45,966.51
(
-0.56%
)
Brent Oil
107.71
(
1.06%
)
Bitcoin
69,698.22
(
-2.17%
)
News Focus
News Focus
Post# of 257259
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122799
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: MRX22 post# 68577

Friday, 11/14/2008 6:25:18 PM

Friday, November 14, 2008 6:25:18 PM

Post# of 257259
>Teva still would have to bust the tenofovir patents to be able to sell generic Truvada.<

By filing a Paragraph-IV certification against Truvada based on only the Orange Book patents for Emtriva, Teva would seem to be implying that the Viread patents will be without force. Alternatively, GILD may not be divulging the full extent of Teva’s Paragraph-IV certifications. In any event, I’ll be interested in seeing the court pleadings when they come out. Regards, Dew

p.s. The quiz question in #msg-33586560 hinges on a different issue than the one above.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now